Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub
Rhea-AI Summary
Aclarion (Nasdaq: ACON) will present at Planet MicroCap Las Vegas 2026 Powered by MicroCapClub on June 17, 2026, at 8:30 AM PT at the Bellagio Resort & Hotel. Executive Chairman Jeff Thramann will host the session and answer investor questions.
According to Aclarion, recent highlights include triple-digit annual Nociscan growth, progress on reimbursement and the CLARITY trial with an interim readout expected in Q4 2026, an expanded AI patent portfolio totaling 64 issued and pending patents, a $2.5 million share repurchase program, and a debt-free balance sheet with cash runway into the second half of 2027.
Investors can access the live webcast via the event link and schedule in-person 1x1 meetings at the Bellagio by registering through the conference platform. Archived webcasts will be available under the Agenda tab on the Planet MicroCap Las Vegas 2026 site.
Positive
- None.
Negative
- None.
News Market Reaction – ACON
In the Jun 10 session, ACON declined 2.91%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BROOMFIELD, Colo., June 10, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms through its Nociscan® platform to help physicians identify the location of chronic low back pain and support improved treatment success rates, today announced that it will be presenting at the Planet MicroCap Las Vegas 2026 Powered by MicroCapClub on Wednesday, June 17, 2026 at 8:30 AM PT at the Bellagio Resort & Hotel. Jeff Thramann, Executive Chairman, will be hosting the presentation and answering questions at the conclusion.
Recent Key Highlights
- Triple-digit annual growth signals accelerating Nociscan adoption and integration into clinical workflows
- Advancing reimbursement and clinical milestones, with CLARITY trial interim readout anticipated in Q4 2026
- Strengthened IP footprint with new AI patent and 64 total issued and pending patents worldwide
- Announced
$2.5 million share repurchase program - Strong balance sheet, no debt and cash runway into the second half of 2027, reinforcing long-term growth strategy
To access the live presentation, please use the following information:
Planet MicroCap Las Vegas 2026 Powered by MicroCapClub
Date: Wednesday, June 17, 2026
Time: 8:30 AM PT
Webcast: https://event.summitcast.com/view/bpjo3VVjZ25pp6SXpUua92/W9gzJg4A3SGnExFmbxcXEs
If you would like to book a 1x1 investor meeting and to attend the Planet MicroCap Las Vegas 2026, please make sure you are registered here: REGISTER
1x1 meetings will be scheduled and conducted in person at the conference venue: Bellagio Resort & Hotel in Las Vegas, NV.
The Planet MicroCap Las Vegas 2026 website is available here: HOME PAGE
If you can’t make the live presentation, all company presentation “webcasts” will be available directly on the conference event platform on this link under the tab “Agenda”: AGENDA
About Planet MicroCap
Planet Microcap hosts the highest quality microcap in-person events in North America. The mission is to bring the best microcap investors, companies, and allocators together to gather, connect, and grow. For more information about Planet MicroCap, please visit: https://planetmicrocap.com/
About MicroCapClub
MicroCapClub is an exclusive forum for experienced microcap investors to share and discuss microcap companies (sub
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. Forward-looking statements in this release include, among others, that we will attend and present at the Planet MicroCap Las Vegas 2026 conference on Wednesday, June 17, 2026 at 8:30 AM PT at the Bellagio Resort & Hotel, interim CLARITY trial readout results will occur in Q4 of 2026, statements regarding the expectation to execute the
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com
Media Contacts:
Jennie Kim
SPRIG Consulting
jennie@sprigconsulting.com
